Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

PHASE4CompletedINTERVENTIONAL
Enrollment

337

Participants

Timeline

Start Date

June 10, 2013

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Cushing's DiseaseAcromegalyNeuroendocrine TumorsPituitary TumorsEctopic ACTH Secreting (EAS) TumorsDumping SyndromeProstate CancerMelanoma Negative for bRAFMelanoma Negative for nRAS
Interventions
DRUG

Pasireotide

Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

DRUG

Cabergoline

Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.

DRUG

Pasireotide LAR

Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.

Trial Locations (94)

27

Recordati Investigative Site, San Isidro

1011

Recordati Investigative Site, Lausanne

1085

Recordati Investigative Site, Budapest

1090

Recordati Investigative Site, Brussels

1200

Recordati Investigative Site, Brussels

1431

Recordati Investigative Site, Sofia

2610

Recordati Investigative Site, Wilrijk

2650

Recordati Investigative Site, Edegem

3000

Recordati Investigative Site, Leuven

4000

Recordati Investigative Site, Liège

8091

Recordati Investigative Site, Zurich

8310

Recordati Investigative Site, Bruges

9000

Recordati Investigative Site, Ghent

10065

Memorial Sloan-Kettering Cancer Center SC, New York

10400

Recordati Investigative Site, Bangkok

10700

Recordati Investigative Site, Bangkok

10990

Recordati Investigative Site, Pulau Pinang

13353

Recordati Investigative Site, Berlin

13385

Recordati Investigative Site, Marseille

14269

Recordati Investigative Site, Mexico City

16132

Recordati Investigative Site, Genova

20149

Milano Investigative Site, Milan

20246

Recordati Investigative Site, Hamburg

23321

Virginia Endocrinology Research SC, Chesapeake

31000

Recordati Investigative Site, Toulouse

33604

Recordati Investigative Site, Pessac

34098

Recordati Investigative Site, Istanbul

34270

Recordati Investigative Site, Durango

34890

Recordati Investigative Site, Istanbul

35128

Recordati Investigative Site, Padua

35340

Recordati Investigative Site, Izmir

40705

Recordati Investigative Site, Taichung

41380

Recordati Investigative Site, Kocaeli

44130

Recordati Investigative Site, Guadalajara

48109

University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor

49100

Recordati Investigative Site, Petah Tikva

49933

Recordati Investigative Site, Angers

59037

Recordati Investigative Site, Lille

60126

Recordati Investigative Site, Ancona

62502

Recordati Investigative Site, Kuala Lumpur

69495

Recordati Investigative Site, Pierre-Bénite

69677

Recordati Investigative Site, Bron

72076

Recordati Investigative Site, Tübingen

81377

Recordati Investigative Site, München

81667

Recordati Investigative Site, München

89081

Recordati Investigative Site, Ulm

90048

Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles

90110

Recordati Investigative Site, Songkhla

92037

Ximed Research SC - SOM230B2412, La Jolla

94275

Recordati Investigative Site, Le Kremlin-Bicêtre

94304

Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford

97080

Recordati Investigative Site, Würzburg

98104

Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle

123317

Recordati Investigative Site, Moscow

197341

Recordati Investigative Site, Saint Petersburg

560054

Recordati Investigative Site, Bangalore

625023

Recordati Investigative Site, Tyumen

632004

Recordati Investigative Site, Vellore

656024

Recordati Investigative Site, Barnaul

89201260

Recordati Investigative Site, Joinville

C1405BCH

Recordati Investigative Site, CABA

B7602CBM

Recordati Investigative Site, Mar del Plata

60430 370

Recordati Investigative Site, Fortaleza

80030-110

Recordati Investigative Site, Curitiba

21941-913

Recordati Investigative Site, Rio de Janeiro

90560 030

Recordati Investigative Site, Porto Alegre

18618-970

Recordati Investigative Site, Botucatu

05403 000

Recordati Investigative Site, São Paulo

B3H 1V7

Recordati Investigative Site, Halifax

N6A 4L6

Recordati Investigative Site, London

H2L 4M1

Recordati Investigative Site, Montreal

H2W 1T8

Recordati Investigative Site, Montreal

115 27

Recordati Investigative Site, Athens

00168

Recordati Investigative Site, Roma

460-0001

Recordati Investigative Site, Nagoya

371 8511

Recordati Investigative Site, Maebashi

650-0017

Recordati Investigative Site, Kobe

783 8505

Recordati Investigative Site, Nankoku

612-8555

Recordati Investigative Site, Kyoto

565 0871

Recordati Investigative Site, Suita

07760

Recordati Investigative Site, Mexico City

9713 GZ

Recordati Investigative Site, Groningen

80 952

Recordati Investigative Site, Gdansk

60-355

Recordati Investigative Site, Poznan

04141

Recordati Investigative Site, Warsaw

50 367

Recordati Investigative Site, Wroclaw

4200-319

Recordati Investigative Site, Porto

011863

Recordati Investigative Site, Bucharest

03722

Recordati Investigative Site, Seoul

06351

Recordati Investigative Site, Seoul

03010

Recordati Investigative Site, Alicante

08041

Recordati Investigative Site, Barcelona

06500

Recordati Investigative Site, Ankara

07070

Recordati Investigative Site, Antalya

All Listed Sponsors
lead

RECORDATI GROUP

INDUSTRY

NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | Biotech Hunter | Biotech Hunter